Indivior Pharmaceuticals (INDV) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Indivior Pharmaceuticals (INDV) has outperformed Viking Therapeutics (VKTX) over the past year, gaining 52.3% versus a loss of 9.5%. Over five years, VKTX leads with a +374.9% price change compared with +127.9% for INDV. Indivior Pharmaceuticals is the larger company by market cap ($4.26 billion vs $3.63 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDV | VKTX |
|---|---|---|
| Share price | $36.13 | $28.54 |
| Market cap | $4.26B | $3.63B |
| 1-day change | +0.64% | +0.56% |
| YTD return | +0.70% | -18.87% |
| 1-year return | +52.32% | -9.50% |
| 5-year return | +127.95% | +374.88% |
| P/E ratio (TTM) | 12.95 | — |
| Forward P/E | 7.40 | — |
| EPS (TTM) | $2.79 | $-4.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.24B | $0 |
| Revenue growth (YoY) | +4.29% | — |
| Net income (latest FY) | $210.00M | $-359.64M |
| Gross margin | 80.23% | — |
| Operating margin | 21.15% | — |
| Net margin | 16.95% | — |
| 52-week high | $42.81 | $43.15 |
| 52-week low | $22.95 | $25.77 |
| Distance from 52-week high | -15.60% | -33.86% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +35.62% | +231.85% |
| Average volume | 2.08M | 4.02M |
| Shares outstanding | 118.03M | 127.17M |
| Employees | 827 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INDV has outperformed VKTX by 61.8 percentage points over the past year.
About Indivior Pharmaceuticals
INDV stock →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
INDV vs VKTX FAQ
Which is bigger, Indivior Pharmaceuticals or Viking Therapeutics?
Indivior Pharmaceuticals (INDV) is larger, with a market capitalization of $4.26B compared with $3.63B for Viking Therapeutics (VKTX).
Which stock has performed better over the past year, INDV or VKTX?
INDV returned +52.32% over the past 12 months, compared with -9.50% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are Indivior Pharmaceuticals and Viking Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.